Giroux, Dorothy J. MS*; Rami-Porta, Ramón MD†; Chansky, Kari MS*; Crowley, John J. PhD*; Groome, Patti A. PhD‡; Postmus, Pieter E. MD, PhD§; Rusch, Valerie MD∥; Sculier, Jean-Paul MD¶; Shepherd, Frances A. MD#; Sobin, Leslie MD**; Goldstraw, Peter MB, FRCS††; On behalf of the International Association for the Study of Lung Cancer International Staging Committee
The objectives of the Lung Cancer Staging Project of the International Association for the Study of Lung Cancer (IASLC)1 have been achieved with the submission of recommendations for the seventh edition of the tumor, node, metastasis (TNM) classification for lung cancer to the International Union Against Cancer and to the American Joint Committee on Cancer. These core recommendations and the methodology used in the analysis of the retrospective database have been published in this Journal,2–6 as well as additional publications on small cell lung cancer, carcinoid tumors, and prognostic factors.7–9
The limitations of the analysis of the retrospective database derive from the fact that most databases that contributed cases to the international database were not designed to study the TNM classification of lung cancer. The most important consequence was that although the clinical or pathologic T status was recorded in most of the databases, few included the finer details, such as the specific anatomic sites of tumor extension. For this reason, most of the descriptors that define T3 and T4 tumors could not be validated in this retrospective study.2 The same is true for the potential subdivision of the N1 and N2 nodal spread based on the number of involved nodes or nodal stations,3 and for the differences in the various forms of M1 disease.4
In addition, subtle differences between nodal maps used in different parts of the world—e.g., the Mountain and Dresler10 modification to the American Thoracic Society map and the Naruke-Japan Lung Cancer Society map—11,12 complicated previous attempts to analyze international data on nodal involvement.
OBJECTIVES OF THE PROSPECTIVE PROJECT
To overcome the limitations of the Retrospective Project, the International Staging Committee (ISC) of the IASLC is proposing a Prospective Project with the general objective to refine future editions of the TNM classification for lung cancer. This would imply the validation of all T-, N-, and M descriptors, with special attention to those that could not be validated with the analysis of the retrospective database, and the validation of descriptors that are not included in the present TNM classification. The specific primary objectives for each T, N, and M component, as well as for other factors, are outlined in Table 1.
These objectives would be achieved by collecting a large prospective international database. This would, as far as possible, correct the geographical omissions and disproportionate spread of treatment modalities, which were inevitable in the retrospective data base, and would include both nonsmall and small cell bronchogenic carcinomas at the time of the initial diagnosis. In addition, at a recent IASLC workshop in London, there was international support for the inclusion of specific neuroendocrine subsets into the prospective data set.13 Pleural mesothelioma is to be covered in a separate data set at a later point.
Based on the experience of the Retrospective Project, the ISC has defined the data required to address the objectives of the Prospective Project. Baseline data to be captured, at the time a decision is made as to first-line treatment of newly diagnosed lung cancer confirmed by histology or cytology, include patient characteristics, baseline laboratory values, treatment modalities, TNM stage, and all supporting evidence. Beyond that, all patients will be followed for survival. The complete set of data elements can be viewed online (http://www.iaslc.org/staging-project.asp).
Patient characteristics include birth date, race, sex, smoking history (never versus former versus current smoker), years since quitting, years smoked, weight loss in previous 6 months, performance status, height, weight, and the specific comorbid factors needed to calculate the Colinet score for each patient: tobacco consumption, renal insufficiency, respiratory comorbidity, cardiovascular comorbidity, neoplastic comorbidity, and alcoholism.
Disease diagnosis descriptors include the date of clinical trial entry (if applicable), method of disease detection, whether diagnosis was based on cytology and/or histology and the dates of each, location of the primary, degree of tumor differentiation, and histologic type. For small cell lung cancer, the presence of paraneoplastic syndrome, such as the syndrome of inappropriate secretion of antidiuretic hormone or ectopic adrenocorticotrophic hormone, and myasthenic syndrome, will also be collected.
Baseline laboratory parameters include lactate dehydrogenase, hemoglobin, calcium, alkaline phosphatase, sodium, white cell count, neutrophil count, platelet count, and albumin, including the upper and lower limits of normal for each laboratory. Other prognostic factors of interest include the maximum standard uptake value for the primary tumor as well as for the nodes and pulmonary function test results of forced vital capacity and forced expiratory volume in 1 second.
TNM will be applied universally to nonsmall cell, small cell, and neuroendocrine lung tumors, in accordance in the seventh edition. The treatment section will first ask whether there was an attempt to remove the primary tumor. If resection was not attempted, a single set of TNM will be collected as representation of “evaluative” cTNM, and treatment information will include whether or not chemotherapy and radiation were given, with sites of radiation collected as well. The basis for pretreatment T, N, and M will be documented in terms of the use of history and physical examination, standard radiology, magnetic resonance imaging, computerized tomography, positron emission tomography, bronchoscopy, or more invasive surgical procedures not involving resection of the primary tumor.
If resection of the primary was attempted, two sets of TNM will be collected: pretreatment cTNM and postsurgical pTNM. The date of the resection attempt, extent, and completeness of resection, according to the proposed completeness of resection definitions of the IASLC,14 will be recorded, with specification of sites of microscopic and macroscopic residual disease. Timing of chemotherapy and radiation to the primary tumor will be recorded relative to the resection attempt (i.e., before versus after versus both).
Pretreatment T-, N-, and M descriptors will be collected for all patients. Pretreatment T descriptors include clinical features and the size and degree of tumor extension. The presence of carcinomatous lymphangitis will also be described in the area of the primary tumor, elsewhere within the lobe of the primary, and involving other areas within the ipsilateral and/or contralateral lung. Nodal assessment by clinical or imaging studies will be recorded separately from biopsy or cytology, according to the IASLC 2009 nodal map.15 Pretreatment N descriptors include the individual assessments of each nodal station as positive or negative for tumor—or alternatively, of each nodal zone. The size and location of the largest node will also be recorded.
A second, parallel set of postsurgical T-, N-, and M descriptors will be collected for patients undergoing resection. The postsurgical T section will also record the extent of visceral pleural invasion as proposed by Travis et al.,16 venous invasion, status of the fissures, presence of lymphatic invasion, and pleural lavage cytology. The postsurgical M section will indicate which, if any, of the M-status findings changed as a result of the resection attempt. Optionally, the number of nodes explored, number of positive nodes, and presence of extracapsular involvement could be registered for N3, N2, and N1 regions.
For patients with multiple tumor nodules considered to be part of a single malignancy, extended data on the size, histology, and distance of additional nodules from the main mass will be collected, organized into three scenarios: the same lobe as the primary, ipsilateral lobes other than the lobe containing the primary tumor, and contralateral lobes.
For the uncommon patient with multiple synchronous primary tumors, staging data from each primary will be recorded separately.
Outcome variables to be collected will include the last date of contact, vital status, and the date of death. Data regarding the availability of tissue or results from molecular studies will also be briefly surveyed to identify potential resources for future collaborative research.
PROPERTY OF THE DATABASE AND PUBLICATION POLICY
Institutions approved by the IASLC Staging Committee for participation in this Prospective Project will preferably enter the data from an inception cohort online using a secure, web-based data entry; however, sites may alternatively petition the ISC to transfer data from an existing database. Access to the online data entry system will be available through the IASLC web site at http://www.iaslc.org, initially to limited institutions in China, Spain, and the United States which have agreed to pilot the system. Designed and administered by Cancer Research and Biostatistics (CRAB), the system will incorporate extensive, between-field logic checks, and provide a query system enabling communication between CRAB and the institutions regarding the data. Transfer of existing, external data will initially be limited to selected partners from the retrospective project and centers that facilitate correction of geographical gaps identified in the retrospective data. Additional retrospective data may be required, however, stricter standards regarding data quality and completeness will be enforced than in the previous study. Each institution will retain full access and publishing rights to its own data; however, the collective database will be the property of the IASLC, and CRAB will be responsible for its management, storage, and analysis.
Publications related to the objectives of the Prospective Project of the IASLC Staging Committee (i.e., publications providing recommendations for changes in the TNM classification) will be planned, researched, analyzed, and written by the members of the respective Subcommittees, and will follow the same authorship pattern used for the publications on the retrospective data: Chairperson of the subcommittee, members of the subcommittee in alphabetical order, Chairman of the Staging Committee, on behalf of the IASLC Staging Committee, and participating institutions.
Table 2 shows the timeline of the Prospective Project.
CALL FOR PARTICIPATION
The objectives of the Prospective Project of the ISC of the IASLC are well defined, and the prospective dataset has been designed to achieve the proposed objectives. The project’s success will depend on both the extent of the international participation and the quality of the data. International representation is needed to ensure that the final staging system applies to genetically diverse populations, who may be subject to differing levels of investigations and care. The Retrospective Project showed that quality of the data is even more important than its size. It will, therefore, be pivotal to collect complete data, especially when registering the elements directly related to the pretreatment and postsurgical classification of lung cancer, the analysis of which is the main objective of this project.
Useful information not related to the anatomic extension of the disease can also be derived from the prospectively registered data. The inclusion of the methods used in the clinical staging will allow us to explore their reliability in those patients undergoing lung resection, in whom the pretreatment and postsurgical classifications can be compared. The IASLC has published consensus guidelines on clinical staging based on the best evidence available in clinical practice.17–19 With the information of the prospective database, the IASLC would be able to review those guidelines based on contemporary data specifically collected for the purpose of staging analysis.
One of the objectives of the TNM classification is to assign a prognosis based on the anatomic extent of the disease. However, there are other factors that influence prognosis of lung cancer that are not related to its anatomic extension. Sex, age and comorbidity,20–22 biologic parameters,23 and molecular and genetic factors are known to influence prognosis but have never been integrated into the TNM classification. Information on comorbidity and basic blood analyses is easily available from most patients. Because the study of molecular and genetic factors is not standardized or universally available, information on the accessibility of these data would be collected, rather than the actual end points. This could facilitate international collaborative research among contributing centers. The maximum standard uptake value, which has shown prognostic relevance,24 will also be registered in those patients undergoing positron emission tomography scan in the pretreatment staging of their tumors.
The prospective registration of all these anatomic and nonanatomic parameters would allow us to address most of the issues that are expected from the ISC of the IASLC.25 That said, the practical limitations of such an undertaking as a worldwide tumor registry must be understood. At current funding levels, the geographic expanse of the project and diversity of languages does not afford the ability to perform site audits or central pathology review or even to reimburse the expense of data collection. Consequently, the ISC will not be able to verify independently whether consecutive patients have been enrolled or to detect errors in the interpretation of source data. On the other hand, one can argue that these data reflect “real world” experience, and an international classification system must be reproducible in the diverse settings in which it is applied. Finally, access to the online registry and data retrieval is a service that has value to participants. Automated consistency checks comparing the assigned T, N, and M categories to the supportive data may actually improve the implementation of staging guidelines over time. We encourage the medical community involved in the diagnosis and treatment of patients with lung cancer to consider collecting data that are compatible with this data set and to contribute these data to the Prospective Project of the IASLC.
To obtain more information about the project, please send an email to email@example.com with “IASLC Staging Project” in the subject line.
IASLC International Staging Committee
P. Goldstraw (Chairperson), Royal Brompton Hospital, Imperial College, London, UK; H. Asamura, National Cancer Centre Hospital, Tokyo, Japan; D. Ball, Peter MacCallum Cancer Centre, East Melbourne, Australia; V. Bolejack, Cancer Research and Biostatistics, Seattle, Washington, USA; E. Brambilla, Laboratoire de Pathologie Cellulaire, Grenoble Cedex, France; P.A. Bunn, University of Colorado Health Sciences, Denver, Colorado; D. Carney, Mater Misericordiae Hospital, Dublin, Ireland; K. Chansky, Cancer Research and Biostatistics, Seattle, Washington, USA; J. Crowley, Cancer Research and Biostatistics, Seattle, Washington, USA; D. Giroux, Cancer Research And Biostatistics, Seattle, Washington, USA; P. Groome, Queen’s Cancer Research Institute, Kingston, Ontario, Canada; P. Van Houtte, Institute Jules Bordet, Bruxelles, Belgium; J. R. Jett, Mayo Clinic, Rochester, Minnesota, USA; C. Kennedy, University of Sydney, Sydney, Australia; H. Kondo, Shizuoka Cancer Centre, Shizuoka, Japan; M. Krasnik, Gentofte Hospital, Copenhagen, Denmark; J. van Meerbeeck, University Hospital, Ghent, Belgium; H. Pass, New York Medical Centre, New York, USA; E.F. Patz, Duke University Medical Center, Durham, North Carolina, USA; P.E Postmus, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; R. Rami-Porta, Hospital Universitario Mutua de Terrassa, Terrassa, Spain; V. Rusch, Memorial Sloan-Kettering Cancer Center, New York, USA; N. Saijo, National Cancer Center Hospital East, Chiba, Japan; J. P. Sculier, Institute Jules Bordet, Bruxelles, Belgium; F.A. Shepherd, University of Toronto, Toronto, Ontario, Canada; L. Sobin, Armed Forces Institute of Pathology, Washington, DC; W. Travis, Memorial Sloan-Kettering Cancer Center, New York, USA; M. Tsuboi, Tokyo Medical University, Tokyo, Japan; E. Vallieres, Swedish Cancer Institute, Seattle, Washington, USA; J. Vansteenkiste, Leuven Lung Cancer Group, Belgium; H. Watanabe, National Cancer Centre Hospital, Tokyo, Japan.
Eli Lilly and Company provided funding to support the International Association for the Study of Lung Cancer (IASLC) Staging Committee’s work to establish a database and to suggest revisions to the sixth edition of the TNM classification for lung cancer (staging) through a restricted grant. Lilly had no input into the committee’s analysis of the data or into their suggestions for revisions to the staging system.
1. Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer International staging project on lung cancer. J Thorac Oncol 2006;1:281–286.
2. Rami-Porta R, Ball D, Crowley J, et al.; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593–602.
3. Rusch VW, Crowley J, Giroux DJ, et al.; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC lung cancer project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:603–612.
4. Postmus PE, Brambilla E, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC lung cancer project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2:686–693.
5. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC lung cancer project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706–714.
6. Groome PA, Bolejack V, Crowley JJ, et al.; IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC lung cancer project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694–705.
7. Shepherd FA, Crowley J, Van Houtte P, et al.; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067–1077.
8. Travis W, Giroux D, Chansky K, et al.; International Staging Committee and Participating Institutions. The IASLC lung cancer staging project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2008;3:1213–1223.
9. Sculier JP, Chansky K, Crowley J, Van Meerbeeck J, Goldstraw P; International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol 2008;3:457–466.
10. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718–1723.
11. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978;76:832–839.
12. Japan Lung Cancer Society. Classification of Lung Cancer. First English Edition. Tokyo: Kanehara Publishing, 2000.
13. Lim E, Goldstraw P, Nicholson AG, et al. Proceedings of the IASLC international workshop on advances in pulmonary neuroendocrine tumours 2007. J Thorac Oncol 2007;3:1194–1201.
14. Rami-Porta R, Wittekind C, Goldstraw P; International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005;49:25–33.
15. Rusch VW, Asamura H, Watanabe H, et al. The IASLC Lung Cancer Staging Project: A proposal for a new international lymph node map in the forthcoming seventh edition of the TMN classification for lung cancer. J Thorac Oncol 2009;4:568–577.
16. Travis W, Brambilla E, Rami-Porta R, et al.; International Staging Committee. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol 2008;3:1384–1390.
17. Goldstraw P, Bureau G, Cullen M, et al. Pretreatment minimal staging for non-small cell lung cancers: a consensus report. Lung Cancer 1991;7:7–9.
18. Goldstraw P, Rocmans P, Ball D, et al. Pretreatment minimal staging for non-small cell lung cancer: an updated consensus report. Lung Cancer 1994;11(Suppl 3):S1–S4.
19. Postmus PE, Rocmans P, Asamura H, et al. Consensus report IASLC workshop Bruges, September 2002: pre-treatment minimal staging for non-small cell lung cancer. Lung Cancer 2003;42(Suppl 1):S3–S6.
20. López-Encuentra A; Bronchogenic Carcinoma Co-operative Group. Comorbidity in operable lung cancer; a multicenter descriptive study on 2992 patients. Lung Cancer 2002;35:263–269.
21. López-Encuentra A, Astudillo J, Cerezal J, et al.; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur J Cardiothorac Surg 2005;27:8–13.
22. López-Encuentra A, Gómez de la Cámara A, Rami-Porta R, et al.; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Previous tumour as a prognostic factor in stage I non-small cell lung cancer. Thorax 2007;62:386–390.
23. Gómez de la Cámara A, López-Encuentra A, Ferrando P, Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumolody and Thoracic Surgery (GCCB-S). Heterogeneity of prognostic profiles in non-small cell lung cancer: too many variables but a few relevant. Eur J Epidemiol 2005;20:907–914.
24. Berghmans T, Dusart M, Paesmans M, et al.; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cacner (NSCLC): a systematic review and meta-analysis (MA) by the European Lung cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6–12.
25. Mountain C. The Odyssey of lung cancer staging: the new frontier. Lung Cancer 2005;49(Suppl 2):S26.